Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

NCT01496989 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

NETWORK

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV-MAG (3,000mcg)
BIOLOGICAL: GENEVAX® IL-12 (100mcg)
BIOLOGICAL: GENEVAX® IL-12 (1000mcg)
BIOLOGICAL: Ad35-GRIN/ENV

Sponsor

International AIDS Vaccine Initiative

Collaborators

[object Object]
[object Object]